Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Pombiliti | cipaglucosidase alfa-atga | Amicus Therapeutics | N-761204 RX | 2023-09-28 | 1 products |
Brand Name | Status | Last Update |
---|---|---|
pombiliti | Biologic Licensing Application | 2024-11-27 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
glycogen storage disease type ii | Orphanet_365 | D006009 | E74.02 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glycogen storage disease type ii | D006009 | Orphanet_365 | E74.02 | 2 | 2 | 4 | — | 4 | 11 |
Glycogen storage disease | D006008 | — | E74.0 | — | — | 1 | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | — | — | — | 1 | 1 |
Lysosomal storage diseases | D016464 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Cipaglucosidase alfa |
INN | cipaglucosidase alfa |
Description | Cipaglucosidase alfa, sold under the brand name Pombiliti, and used in combination with miglustat, is a medication used for the treatment of glycogen storage disease type II (Pompe disease). Cipaglucosidase alfa is a recombinant human acid α-glucosidase enzyme replacement therapy that provides an exogenous source of acid α-glucosidase.
|
Classification | Enzyme |
Drug class | enzymes |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL4594329 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB16708 |
UNII ID | 4SED7F4BSG (ChemIDplus, GSRS) |